Continuous Delivery of Levodopa in Patients With Advanced Idiopathic Parkinsons Disease - Cost-benefit

Continuous Delivery of Levodopa/Carbidopa (Duodopa) in Patients With Advanced Idiopathic Parkinsons Disease - a Health Economic Evaluation

An open, observational health economic study to estimate marginal cost and health consequences of replacing conventional Parkinsons disease therapy with intraduodenal levodopa administered continuously

Inclusion Criteria:

• Clinical diagnosis of of idiopathic Parkinsons disease
• Motor fluctuations despite optimised per oral treatment

Exclusion Criteria:

• Severe dementia, confusion, psychosis or depression
• Patients with contraindications against levodopa treatment